Pharmacokinetics and pharmacodynamics of the urotensin-II receptor antagonist palosuran in macroalbuminuric, diabetic patients.

被引：0
|
作者：
Sidharta, PN
Wagner, FD
Jungik, A
Halabi, A
Dingemanse, J
机构：
[1] Actel Pharmaceut Ltd, Allschwil, Switzerland
[2] 3ClinRes AG, Hennigsdorf, Germany
[3] PHAROS GmbH, Ulm, Germany
[4] IKP GmbH, Kiel, Germany
来源：
JOURNAL OF CLINICAL PHARMACOLOGY | 2005年 / 45卷 / 09期
关键词：
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
47
引用
收藏
页码：1078 / 1078
页数：1
相关论文
共 50 条
  • [1] Pharmacodynamics and pharmacokinetics of the urotensin II receptor antagonist palosuran in macroalbuminuric, diabetic patients
    Sidharta, Patricia N.
    Wagner, Frank D.
    Bohnemeier, Holger
    Jungnik, Arvid
    Halabi, Atef
    Kraehenbuehl, Stephan
    Chadha-Boreham, Harbajan
    Dingemanse, Jasper
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2006, 80 (03) : 246 - 256
  • [2] Pharmacokinetics and Pharmacodynamics of the Urotensin-II Receptor Antagonist Palosuran in Healthy Male Subjects
    Sidharta, Patricia N.
    van Giersbergen, Paul L. M.
    Dingemanse, Jasper
    JOURNAL OF CLINICAL PHARMACOLOGY, 2009, 49 (10): : 1168 - 1175
  • [3] Pharmacokinetics and pharmacodynamics of the urotensin-II receptor antagonist palosuran in healthy human subjects
    Sidharta, PN
    van Giersbergen, PLM
    Schaarschmidt, D
    Dingemanse, J
    JOURNAL OF CLINICAL PHARMACOLOGY, 2004, 44 (10): : 1192 - 1192
  • [4] Multiple-Dose Pharmacokinetics, Pharmacodynamics, and Safety of the Urotensin-II Receptor Antagonist Palosuran in Healthy Male Subjects
    Sidharta, Patricia N.
    van Giersbergen, Paul L. M.
    Dingemanse, Jasper
    PHARMACOLOGY, 2018, 102 (5-6) : 339 - 346
  • [5] Multiple-dose tolerability, safety, pharmacokinetics, and pharmacodynamics of the urotensin-II receptor antagonist palosuran in healthy human subjects
    Sidharta, PN
    van Giersbergen, PLM
    Schaarschmidt, D
    Dingemanse, J
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2005, 60 (06) : 677 - 678
  • [6] The urotensin-II receptor antagonist palosuran improves pancreatic and renal function in diabetic rats
    Clozel, M
    Hess, P
    Qiu, CB
    Ding, SS
    Rey, M
    JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2006, 316 (03): : 1115 - 1121
  • [7] The effects of the urotensin-II receptor antagonist palosuran treatment on the corpora cavernosa of streptozotocin-induced diabetic rats
    Olukman, Murat
    Can, Cenk
    Ulker, Sibel
    Uyanikgil, Yigit
    Cavusoglu, Turker
    Duzenli, Neslihan
    Coskunsever, Deniz
    Kozcu, Fatma G.
    ASIAN JOURNAL OF UROLOGY, 2025, 12 (01) : 116 - 126
  • [8] Effect of the urotensin-II receptor antagonist palosuran on secretion of and sensitivity to insulin in patients with Type 2 diabetes mellitus
    Sidharta, Patricia N.
    Rave, Klaus
    Heinemann, Lutz
    Chiossi, Eleonora
    Kraehenbuehl, Stephan
    Dingemanse, Jasper
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2009, 68 (04) : 502 - 510
  • [9] Effect of the urotensin-II receptor antagonist palosuran on secretion of and sensitivity to insulin in patients with type 2 diabetes mellitus.
    Sidharta, Patricia N.
    Rave, Klaus
    Heise, Tim
    Chiossi, Eleonora
    Dingemanse, Jasper
    JOURNAL OF CLINICAL PHARMACOLOGY, 2006, 46 (09): : 1083 - 1083
  • [10] Effect of the Urotensin Receptor Antagonist Palosuran in Hypertensive Patients With Type 2 Diabetic Nephropathy
    Vogt, Liffert
    Chiurchiu, Carlos
    Chadha-Boreham, Harbajan
    Danaietash, Parisa
    Dingemanse, Jasper
    Hadjadj, Samy
    Krum, Henry
    Navis, Gerjan
    Neuhart, Eric
    Parvanova, Aneliya I.
    Ruggenenti, Piero
    Woittiez, Arend Jan
    Zimlichman, Reuven
    Remuzzi, Giuseppe
    de Zeeuw, Dick
    HYPERTENSION, 2010, 55 (05) : 1206 - 1209
12345